Molecular imaging of estrogen receptors

Michel van Kruchten

Molecular imaging of estrogen receptors

Michel van Kruchten

Research output: Thesis › Thesis fully internal (DIV)

2012 Downloads (Pure)

Abstract

For patients with estrogen receptor (ER) positive breast cancer, endocrine therapy plays a major role in both the adjuvant and palliative setting. For adequate treatment decision-making it is crucial to obtain up-to-date information on the ER-status of the tumor(s), since ER-expression is the sole predictor for response to endocrine therapy. Moreover, ER-status can change during the course of disease in up to 30% of the patients, and therefore treatments based on the ER-status of the primary tumor may be inadequate. Positron emission tomography (PET) imaging of ER-expression by use of the tracer 16α-[18F]fluoro-17β-oestradiol (FES) can give functional information about the ER-status of all lesions within the body. The aim of this thesis is to address the clinical potential of the FES-PET technique in breast and ovarian cancer patients.

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	University of Groningen
Supervisors/Advisors	Hospers, Geke, Supervisor de Vries, Liesbeth, Supervisor Glaudemans, Andor, Co-supervisor de Vries, Erik, Co-supervisor Boven, E., Assessment committee, External person Nijman, Hans, Assessment committee van der Wall, Elsken, Assessment committee, External person
Award date	17-Jun-2015
Place of Publication	[Groningen]
Publisher	University of Groningen
Print ISBNs	978-90-367-7944-9
Electronic ISBNs	978-90-367-7943-2
Publication status	Published - 2015

Access to Document

Title and contentsFinal publisher's version, 874 KB
Chapter 1Final publisher's version, 228 KB
Chapter 2Final publisher's version, 5.28 MB
Chapter 3Final publisher's version, 3.76 MB
Chapter 3AFinal publisher's version, 1.49 MB
Chapter 4Final publisher's version, 1.29 MB
Chapter 5Final publisher's version, 1.41 MB
Chapter 6Final publisher's version, 5.73 MB
Chapter 7Final publisher's version, 1.67 MB
Chapter 8Final publisher's version, 1.67 MB
Chapter 9Final publisher's version, 230 KB
Supplemental filesFinal publisher's version, 577 KB
ReferencesFinal publisher's version, 397 KB
DankwoordFinal publisher's version, 138 KB
PublicationsFinal publisher's version, 249 KB
Complete dissertationFinal publisher's version, 21.8 MB
PropositionsFinal publisher's version, 48.7 KB

Cite this

@phdthesis{6db89f542516487dbdb550a7af0f030f,

title = "Molecular imaging of estrogen receptors",

abstract = "For patients with estrogen receptor (ER) positive breast cancer, endocrine therapy plays a major role in both the adjuvant and palliative setting. For adequate treatment decision-making it is crucial to obtain up-to-date information on the ER-status of the tumor(s), since ER-expression is the sole predictor for response to endocrine therapy. Moreover, ER-status can change during the course of disease in up to 30% of the patients, and therefore treatments based on the ER-status of the primary tumor may be inadequate. Positron emission tomography (PET) imaging of ER-expression by use of the tracer 16α-[18F]fluoro-17β-oestradiol (FES) can give functional information about the ER-status of all lesions within the body. The aim of this thesis is to address the clinical potential of the FES-PET technique in breast and ovarian cancer patients.",

author = "{van Kruchten}, Michel",

year = "2015",

language = "English",

isbn = "978-90-367-7944-9",

publisher = "University of Groningen",

school = "University of Groningen",

}

TY - THES

T1 - Molecular imaging of estrogen receptors

AU - van Kruchten, Michel

PY - 2015

Y1 - 2015

N2 - For patients with estrogen receptor (ER) positive breast cancer, endocrine therapy plays a major role in both the adjuvant and palliative setting. For adequate treatment decision-making it is crucial to obtain up-to-date information on the ER-status of the tumor(s), since ER-expression is the sole predictor for response to endocrine therapy. Moreover, ER-status can change during the course of disease in up to 30% of the patients, and therefore treatments based on the ER-status of the primary tumor may be inadequate. Positron emission tomography (PET) imaging of ER-expression by use of the tracer 16α-[18F]fluoro-17β-oestradiol (FES) can give functional information about the ER-status of all lesions within the body. The aim of this thesis is to address the clinical potential of the FES-PET technique in breast and ovarian cancer patients.

AB - For patients with estrogen receptor (ER) positive breast cancer, endocrine therapy plays a major role in both the adjuvant and palliative setting. For adequate treatment decision-making it is crucial to obtain up-to-date information on the ER-status of the tumor(s), since ER-expression is the sole predictor for response to endocrine therapy. Moreover, ER-status can change during the course of disease in up to 30% of the patients, and therefore treatments based on the ER-status of the primary tumor may be inadequate. Positron emission tomography (PET) imaging of ER-expression by use of the tracer 16α-[18F]fluoro-17β-oestradiol (FES) can give functional information about the ER-status of all lesions within the body. The aim of this thesis is to address the clinical potential of the FES-PET technique in breast and ovarian cancer patients.

M3 - Thesis fully internal (DIV)

SN - 978-90-367-7944-9

PB - University of Groningen

CY - [Groningen]

ER -